SCHEMBL6662332

SCHEMBL6662332

CC(C)[C@H](N)C(=O)OCCCCNc1ccc(OC(=O)C(F)(F)F)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NSD2 O96028 3/20 0.39
POLB P06746 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TOP2B Q02880 2/20 0.36
NPC1 O15118 1/20 0.35
MTOR P42345 1/20 0.35
RAB9A P51151 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
MAPT P10636 5/20 0.33
MAPK1 P28482 4/20 0.33
NPSR1 Q6W5P4 4/20 0.33
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
EGFR P00533 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6662493 0.98 MEN1 (0.41) BLMMEN1KMT2ANSD2POLB
SCHEMBL6666092 0.91 MEN1 (0.42) BLMMEN1KMT2ANSD2POLB
SCHEMBL6663782 0.91 ELANE (0.35) BLMMEN1KMT2ANSD2POLB
SCHEMBL6663778 0.87 ELANE (0.39) BLMMEN1KMT2ANSD2POLB
SCHEMBL7111975 0.85 TLR2 (0.39) BLMMEN1KMT2ANSD2POLB
Trifluoroacetic Acid SCHEMBL6662329 0.84 MEN1 (0.42) BLMMEN1KMT2ANSD2POLB
SCHEMBL6663922 0.84 MEN1 (0.43) BLMMEN1KMT2ANSD2POLB
Trifluoroacetic Acid SCHEMBL6662615 0.82 MEN1 (0.44) BLMMEN1KMT2ANSD2POLB
SCHEMBL6666903 0.81 NPC1 (0.47) BLMMEN1KMT2ANSD2POLB
Trifluoroacetic Acid SCHEMBL6663121 0.80 MAPT (0.47) BLMMEN1KMT2ANSD2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1087935-B1 ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS BTG INT LTD (GB) 2004-08-18 EP disclosed
US-20030203975-A1 Anti-cancer agents BTG INTERNATIONAL LIMITED (GB) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203975-A1 Anti-cancer agents TOP2B, TOP2A, TOP1 BLM 1397/4885MEN1 3787/4885KMT2A 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.